 This protocol is a double blinded randomized placebo trial and 2 groups will be followed. The primary end-point of this research is to correlate the serum testosterone with the flow-mediated dilatation of the brachial artery FMDAB, circulating levels of sICAM-1, sVCAM-1, E-selectin and progenitor endothelial cells. The secondary end-points are the evaluation of metabolic parameters weight, abdominal circumference, glycaemia, total cholesterol, fractions and triglycerides, HOMA index and bioimpedanciometry parameters and hormonal parameters total testosterone levels, SHBG, LH, FSH and Estradiol. 